International Review of Neurobiology

Erscheinungsjahr 1998
ISBN: 978-0-12-366842-4
Verlag: ACADEMIC PR INC

Buch, Englisch, Band 42, 345 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 644 g

Reihe: International Review of Neurob

Volume 42 presents an in-depth review on Alzheimer's Disease as well as a look at several transcription factors.

Zielgruppe

Audience: Researchers and graduate students in neuroscience, genetics of cells, pharmacology, biology, and physiology.

Autoren/Hrsg.

Bradley, Ronald J.

Harris, R. Adron

Jenner, Peter

Weitere Mitwirkende

Bradley, Ronald J.

Harris, Robert Adron

Jenner, Peter

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft
• Naturwissenschaften Biowissenschaften Biowissenschaften Neurobiologie, Verhaltensbiologie

Inhaltsverzeichnis

M.A. Smith, Alzheimer Disease W.D. Dietrich, Neurobiology of Stroke M.P. Mattson, Free Radicals, Calcium, and Synaptic Plasticity-Cell Death Continuum: Emerging Roles of the Transcription Factor NFkB K. Pennypacker, AP-1 Transcription Factors: Short- and Long-Term Modulators of Gene Expression in the Brain I. Mody, Ion Channels in Epilepsy X. Bi, S. Standley, and M. Baudry, Posttranslational Regulation of Ionotropic Glutamate Receptors and Synaptic Plasticity B. Vafa and P.R. Schofield, Heritable Mutations in the Glycine, GABAA, and Nicotinic Acetycholine Receptors Provide New Insights into the Ligand-Gated Ion Channel Receptor Superfamily

Über Autor(innen)

Jenner, Peter
Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson's disease. He has spent the major part of his career at King's College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King's College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders. Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson's disease patient-carer groups across the UK.